基本信息
浏览量:0
职业迁徙
个人简介
Clinical Specialties: Pulmonary Physiology, Cellular and Molecular Biology, Regenerative Medicine
Research
Dr. Hoffman has extensive experience, publications (~100), and patents (4) concerning novel methods of evaluation or therapies in spontaneous and experimental disease models in large animals. He also has ~15 yrs experience specifically in the development of preclinical large animal models in accordance with Good Laboratory Practices (GLP), including as PI/PD in a current study funded by NIH (RO1-HL112987-01A1) “Autologous Lung Derived Mesenchymal Stromal Cell Therapy for Emphysema”. Importantly this active study includes GLP-like pre-clinical studies in a large animal (sheep) model of emphysema followed by the first-in-human Phase 1 investigation of autologous LMSCs therapy for advanced emphysema in years 4-5, the latter under the direction of Edward P. Ingenito MD, PhD (PD/PI, Brigham and Womens Hospital).
Previously Drs. Hoffman and Ingenito developed major advances in human emphysema therapy, specifically non-surgical methods for lung volume reduction which are currently in Phase III again successfully linking pre-clinical large animal models with human studies. In addition, Dr. Hoffman’s laboratory serves as a Regenerative Medicine / Stem Cell core and project leader on several studies involving canine, feline, and avian species funded by a variety of Foundations and industry partners.
These multifaceted experiences have given the PD/PI the experience to lead multi-disciplinary projects involving stem cell implantations, bioengineering technologies, large animal experimental or spontaneous models, cell-molecular biology, biomarker analyses, clinical trial design, and FDA (GLP, GCP, GMP) compliance.
Research
Dr. Hoffman has extensive experience, publications (~100), and patents (4) concerning novel methods of evaluation or therapies in spontaneous and experimental disease models in large animals. He also has ~15 yrs experience specifically in the development of preclinical large animal models in accordance with Good Laboratory Practices (GLP), including as PI/PD in a current study funded by NIH (RO1-HL112987-01A1) “Autologous Lung Derived Mesenchymal Stromal Cell Therapy for Emphysema”. Importantly this active study includes GLP-like pre-clinical studies in a large animal (sheep) model of emphysema followed by the first-in-human Phase 1 investigation of autologous LMSCs therapy for advanced emphysema in years 4-5, the latter under the direction of Edward P. Ingenito MD, PhD (PD/PI, Brigham and Womens Hospital).
Previously Drs. Hoffman and Ingenito developed major advances in human emphysema therapy, specifically non-surgical methods for lung volume reduction which are currently in Phase III again successfully linking pre-clinical large animal models with human studies. In addition, Dr. Hoffman’s laboratory serves as a Regenerative Medicine / Stem Cell core and project leader on several studies involving canine, feline, and avian species funded by a variety of Foundations and industry partners.
These multifaceted experiences have given the PD/PI the experience to lead multi-disciplinary projects involving stem cell implantations, bioengineering technologies, large animal experimental or spontaneous models, cell-molecular biology, biomarker analyses, clinical trial design, and FDA (GLP, GCP, GMP) compliance.
研究兴趣
论文共 5 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn